Beyond the Herceptin hype…

1 March 2006 0

Herceptin may turn out to be the biggest advance in treating breast cancer since tamoxifen. But if we are to prevent soaring drugs bills eating up our health budgets or barring Europe’s poorer patients from [more]

... [ more ]

Phase III trials in oncology

1 March 2006 0

Survival data from phase III trials can be very misleading because patients are not offered the best follow-up therapy argue Siegfried Seeber and Ada Braun in CancerWorld’s new Forum section. Emma Mason canvassed clinical trial [more]

... [ more ]

Mr Hodgkin’s disease

1 March 2006 0

Volker Diehl cultured the cells that characterise Hodgkin’s disease when everyone else had failed. He has high hopes that molecular medicine will throw light on many questions that remain unanswered. But he stresses that it [more]

... [ more ]

A trial of strength

1 March 2006 0

Patients, doctors, academic researchers and the World Health Organization all want industry to be a lot more open about the drugs they are trialling. The industry is pleading commercial confidentiality. The two sides are locked [more]

... [ more ]
UA-77507851-1